Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • vilanterol

    Quote from the article: Without adapting JCA to include assessment of real-world data and broader benefits, vaccines may be undervalued

    Is Joint Clinical Assessment (JCA) appropriate for assessing the broader value of vaccines?

    By Emily Morton-West

    Amiculum

    - PMLiVE

    A Call to Action: Bridging the Adult Immunization Divide

    Over the past few years, as new diseases have emerged or reemerged, a host of new vaccines have become available while many others are in the pipeline. For older adults,...

    Medscape Education

    - PMLiVE

    GSK and Hengrui enter multi-programme collaboration agreement worth $12bn

    The deal includes a PDE3/4 inhibitor in clinical development for COPD

    - PMLiVE

    Sanofi and Kling Bio partner to accelerate discovery of neutralising antibodies

    The alliance will centre on Kling’s B cell immortalisation and screening platform Kling-Select

    - PMLiVE

    Merck to expand respiratory disease portfolio with $10bn Verona acquisition

    The deal includes a drug approved in the US for chronic obstructive pulmonary disease

    - PMLiVE

    AstraZeneca shares late-stage results for Airsupra in mild asthma patients

    More than ten million asthma exacerbations occur in the US every year

    - PMLiVE

    AstraZeneca’s triple-combination COPD therapy shows promise in uncontrolled asthma

    Up to 262 million people worldwide are affected by the chronic respiratory disease

    - PMLiVE

    Chiesi report highlights incorrect inhaler use among UK asthma patients

    The long-term lung condition affects around 7.2 million people in the UK

    - PMLiVE

    Gilead and LEO enter inflammatory disease partnership worth up to $1.7bn

    Targeting STAT6 has shown potential in treating a broad population of inflammatory disease patients

    - PMLiVE

    UK researchers uncover first new asthma and COPD attack treatment in 50 years

    The phase 2 study showed that benralizumab could be re-purposed for use in emergency settings

    - PMLiVE

    AstraZeneca/Avillion share positive phase 3 results for asthma rescue treatment Airsupra

    The chronic respiratory disease is estimated to affect up to 262 million people globally

    - PMLiVE

    Sanofi/Regeneron’s Dupixent approved by MHRA to treat uncontrolled COPD

    Approximately 1.4 million people in the UK have been diagnosed with the respiratory disease

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links